Creatine Supplements for Cancer Patients: More Muscle Strength or an Uncertain Risk?

Biological Basis

• Creatine ↔ Phosphocreatine conversion during short, high-intensity efforts rapidly regenerates ATP.
• Outside muscle, it also acts as an energy buffer in the brain and heart .
• Mitochondrial function and oxidative stress control are also thought to be indirectly influenced.

Its Place in Sports Science

Organizations such as the International Society of Sports Nutrition and American sports medicine bodies recognize creatine as an effective ergogenic aid . In particular:

• Muscle mass and strength increase
• Acute exercise capacity improves (high intensity, short duration)
• In older adults, resistance exercise combined with creatine provides greater benefit

⚙️ Potential Mechanisms of Action

• Anaerobic energy capacityincreases (ATP regeneration accelerates).
• Protein breakdown decreases, helping preserve muscle mass.
• Mitochondrial function may be supported and reactive oxygen species regulated.

❗ Clinical Practice Note

Success in athletes should not be expected in cancer , a multifactorial condition, to the same extent . The following section examines clinical evidence in cancer patients.

📊 A Weight-Gain Study in Advanced Disease

In 263 patients with advanced (incurable) disease, a randomized trial of creatine supplementation (maintenance after a loading dose) found it unable to achieve the expected weight gain of 10% or more in the first month more effectively than placebo (P = 1.00).

Appetite and quality-of-life scores also did not differ significantly between the groups.

A Colorectal Cancer Study

In 31 colorectal cancer patients, 8 weeks of creatine supplementation (20 g/day → 5 g/day) did not significantly improve muscle mass, function, or quality of life . However, an increase was observed in a measure of body cell mass and integrity , the phase angle , suggesting a potentially positive effect at the cellular level.

Hormone Therapy and Breast Cancer Studies

• Prostate cancer: In 55 men receiving androgen deprivation therapy (ADT), creatine supplementation provided no additional benefit beyond resistance exercise (P = 0.078–0.951).
• Breast cancer: Short-term creatine supplementation in 19 patients after treatment (7 days, 20 g/day) produced no significant difference in muscle strength or performance.

Clinical Assessment

These results show that creatine's marked effects in athletes are insufficient against the multifactorial biology of cancer cachexia . Muscle loss is caused not only by energy deficiency but also by cytokine storms, inflammation, hormonal changes, and tumor metabolism.

Tumor Suppression (Through Immunity)

• Creatine intake may improve energy availability for antitumor immune effectors such as CD8 T cells .
• This has been associated with enhanced cytotoxic responses and suppressed tumor growth in the tumor microenvironment.
• Proposed mechanism: mitochondrial creatine kinase -mediated energy buffering → prevention of ETC stalling → regulation of reactive oxygen species.

Note: These findings are from animal/cell studies; no corresponding clinical benefit has yet been confirmed in humans.

⚠️ Findings Suggesting Promotion of Metastasis

• In some models, creatine increased colorectal and breast cancer cells' Smad2/3 activation -mediated invasion and metastasis potential.
• This is associated with accelerated TGF-β/Smad pathway-mediated epithelial–mesenchymal transition (EMT) processes.
• Conclusion: This mechanism, conflicting with immune-supporting effects, requires caution in clinical use.

Note: The findings are preclinical and cannot be generalized without human data, but they matter for the risk–benefit balance .

💬 Clinical Commentary

The opposing preclinical findings of suppression and increased metastasis support limiting creatine use in cancer patients until evidence provides clarity . Because clinical trials have not demonstrated significant functional gains, potential risks related to tumor biology weigh against routine use .

⚠️ Common Side Effects

• Gastrointestinal irritation: Nausea, abdominal discomfort, or diarrhea may occur.
• Muscle cramps and headache: Particularly associated with high doses or inadequate fluid intake.
• Weight gain due to fluid retention: Creatine draws water into muscles, potentially causing a misleading increase in measured weight.
• Rare: A temporary increase in the burden on kidney function has been reported; monitor particularly in patients taking nephrotoxic drugs concurrently.

Drug and Food Interactions

• Interaction with caffeine: Long-term or high-dose caffeine use may weaken creatine's performance effects.
• Use with diuretics: May increase dehydration risk.
• Drugs affecting the kidneys: Concurrent use with nephrotoxic chemotherapy such as cisplatin or ifosfamide is not recommended.

💬 Clinical Commentary

In cancer patients, electrolyte balance, fluid status, and kidney function often show treatment-related fluctuations . Even if creatine use is considered, it should therefore be under oncology team and dietitian supervision .

📌 Key Points

• Weight gain / Appetite / Quality of life: No superiority over placebo in the large randomized trial.
• Muscle mass and function: No additional clinical benefit in colorectal, prostate (during ADT), or breast cancer studies.
• Cellular marker: Although phase angle improved, gains translating into everyday life were not confirmed.
• Tumor biology: Despite findings supporting CD8 T-cell responses, the potential for increased metastasis through Smad2/3 is concerning.

Clinical Recommendation

Creatine supplementation in cancer patients should not be routinely recommended. If considered, individualize its use with the oncology team and clinical dietitian , taking kidney function, fluid balance, and concurrent treatments into account.

Looking Ahead

In interventions targeting cachexia, treatment-related fatigue, and cognitive impairment, energy metabolism remains a promising target. However, until creatine's potential effects on the tumor microenvironment are clarified, safety-focused, randomized clinical trials are needed to establish the benefit–risk balance.